This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GTx: Survival Spin Job Follows Enobosarm Study Flop

GTXI Chart GTXI data by YCharts

MEMPHIS ( TheStreet) -- Don't for a second believe GTx (GTXI) CEO Mitch Steiner's B.S. spin about a potential survival benefit emerging from the failed phase III studies of enobosarm. Steiner is simply desperate to keep his company's stock price trading above cash where it belongs.

GTx shares are down 62% to $1.57 following the disclosure Monday that enobosarm failed to increase lean body mass and improve physical function across two phase III studies of non-small cell lung cancer patients.

The negative trial results for enobosarm, a selective androgen receptor modulator (SARM), come as no surprise to any investor who dug deep into the previously reported -- and deeply flawed -- phase II study. [GTx shares are down almost 80% since I outlined the significant risks to the enobosarm studies.]

Now, let's discuss Steiner's ridiculous claim that enobosarm might be helping these lung cancer patients live longer.

Steiner says lung cancer patients who gained lean body mass during the course of the trials -- "enobosarm responders" -- appear to be living longer than the patients who continue to lose lean body mass i.e. the "enobosarm non responders."

Take a moment to let the derpish obviousness of this statement sink in. Patients who respond to a drug demonstrate a benefit compared to those who do not. Um... okay? This revelation and $2 will buy Steiner a tall coffee at Starbucks. It will also get him laughed out of meetings with U.S. and European regulators when he tries to convince them to approve enobosarm on two failed clinical trials.

GTx is engaging in classic biotech mis-direction. There is no credible evidence from these trials that enobosarm is associated at all with a survival benefit. [Memo to Steiner: Perhaps some lung cancer patients are living longer because they're actually responding to chemotherapy. You ever think of that?] The company admits as much in today's press release:

"In the safety analysis of survival, there was no evidence of a difference between patients treated with enobosarm and placebo in either clinical trial."

Anything other claims about survival made by Steiner is just classic biotech mis-direction. Don't fall for it.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GTXI $0.70 -0.01%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs